Clopidogrel-induced thrombotic microangiopathy: a case report.
Thais Lizondo LópezAina Font I BarcelóCarlos García GutiérrezMiquel BlascoIgnacio GrafiaCarla BastidaPedro Castro-RebolloDolors Soy-MunerPublished in: European journal of hospital pharmacy : science and practice (2024)
Thrombotic microangiopathy is a serious condition that can be precipitated by exposure to certain medications. Although rare, it is life threatening and requires a high index of clinical suspicion, appropriate laboratory testing and immediate cessation of the offending agent. We present a case of a 75-year-old man with a history of ischaemic heart disease treated with clopidogrel and aspirin. One month after initiating the treatment he developed microangiopathic haemolytic anaemia and thrombocytopenia. Extensive clinical and laboratory investigations suggested thrombotic microangiopathy secondary to clopidogrel. The drug was immediately discontinued and treatment with intravenous corticosteroids was started. Within a week the patient's laboratory parameters normalised, indicating successful recovery. This case highlights the role of early detection and immediate discontinuation of suspected medication in the effective management of clopidogrel-induced thrombotic microangiopathy. Healthcare professionals should consider drug-induced thrombotic microangiopathy as a possible diagnosis in patients receiving clopidogrel who present with thrombocytopenia and microangiopathic haemolytic anaemia.
Keyphrases
- drug induced
- acute coronary syndrome
- antiplatelet therapy
- liver injury
- percutaneous coronary intervention
- high glucose
- adverse drug
- low dose
- healthcare
- coronary artery disease
- pulmonary embolism
- high dose
- randomized controlled trial
- pulmonary hypertension
- type diabetes
- case report
- oxidative stress
- atrial fibrillation
- study protocol
- iron deficiency